Deciphera Pharmaceuticals (DCPH) Tops Q3 EPS by 17c

Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q3 EPS of ($1.13), $0.17 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $15.5 million versus the consensus estimate of $7.05 million.

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Empire Petroleum posts $11.1M revenue in Q2 2026, narrows net loss
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform